[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
Dec 10/24, 2012

Moderate Renal Impairment and Risk of Bleeding With AnticoagulationComment on “Enoxaparin Outcomes in Patients With Moderate Renal Impairment”

Author Affiliations

Author Affiliation: Department of Medicine, University of California, San Francisco.

Arch Intern Med. 2012;172(22):1718-1720. doi:10.1001/2013.jamainternmed.456

Bleeding is the most feared complication of anticoagulant therapy and, unfortunately, it is not uncommon. The 2011-2012 National Patient Safety Goals mandate efforts to “reduce the likelihood of patient harm associated with the use of anticoagulant therapy.”1 This is a call for coordinated efforts to decrease adverse events related to anticoagulant therapy, with recommendations for improved oversight and evidence-based management of these agents in the inpatient and outpatient settings.

First Page Preview View Large
First page PDF preview
First page PDF preview
×